Antoine G Tohmeh1, William D Smith. 1. Northwest Orthopaedic Specialists, 212 East Central, Suite 140, Spokane, WA, 99208, USA, tohmeh@comcast.net.
Abstract
PURPOSE: To evaluate the clinical and radiographic outcomes following total disc arthroplasty using the XL TDR(®) Lumbar Disc in the treatment of patients with symptomatic degenerative disc disease at one level between L1-2 and L4-5. METHODS: Data were compiled from two centers participating in a prospective, multi-center Food and Drug Administration-approved investigational device exemption clinical trial enrolling patients with single-level lumbar degenerative disc disease unresponsive to non-operative treatment. Longitudinal outcomes were evaluated through 3-year follow-up and included patient-reported pain, function, and general health, as well as radiographic measures such as maintenance of disc height and range of motion. RESULTS: The two-center cohort included 64 treated patients, 42 % female, averaging 45.3 years of age (range 26-67). The majority of procedures were performed at the L4-5 level (75 %), uncomplicated, with minimal blood loss (88 % 0-50 cc), and in an outpatient setting (93.8 %). Postoperative events included 10 patients (15.6 %) with new hip flexion weakness, 7 (10.9 %) with new lower extremity weakness, and 10 (15.6 %) with new lower extremity sensory deficits, all resolved by 3 months in all but two patients whose deficits were prolonged but eventually resolved. Average disc height increased postoperatively from 7.2 to 12.1 mm (69 %), and was 10.7 mm (49 % increase from preoperative) at 3 years. Flexion/extension range of motion averaged 5.9° (SD 4.8°) at 3 years, and was not statistically different from preoperative (p = 0.471). Heterotopic ossification interfering with segmental motion was noted in 3 patients (10.3 %) at 3 years, none ankylosed (Grade IV). Postoperative improvement in patient-reported outcomes was significant (p < 0.01 for all measures) and maintained through 3-year follow-up. Satisfaction with results was reported by 85 % (51/60) of patients at 2 years and 93 % (28/30) at 3 years. There were no revisions through 3 years postoperative. CONCLUSIONS: The results following XL TDR show good clinical and radiographic outcomes out to 3 years postoperative, with clinically significant improvements in pain, function, and general health, few complications, and high patient satisfaction.
PURPOSE: To evaluate the clinical and radiographic outcomes following total disc arthroplasty using the XL TDR(®) Lumbar Disc in the treatment of patients with symptomatic degenerative disc disease at one level between L1-2 and L4-5. METHODS: Data were compiled from two centers participating in a prospective, multi-center Food and Drug Administration-approved investigational device exemption clinical trial enrolling patients with single-level lumbar degenerative disc disease unresponsive to non-operative treatment. Longitudinal outcomes were evaluated through 3-year follow-up and included patient-reported pain, function, and general health, as well as radiographic measures such as maintenance of disc height and range of motion. RESULTS: The two-center cohort included 64 treated patients, 42 % female, averaging 45.3 years of age (range 26-67). The majority of procedures were performed at the L4-5 level (75 %), uncomplicated, with minimal blood loss (88 % 0-50 cc), and in an outpatient setting (93.8 %). Postoperative events included 10 patients (15.6 %) with new hip flexion weakness, 7 (10.9 %) with new lower extremity weakness, and 10 (15.6 %) with new lower extremity sensory deficits, all resolved by 3 months in all but two patients whose deficits were prolonged but eventually resolved. Average disc height increased postoperatively from 7.2 to 12.1 mm (69 %), and was 10.7 mm (49 % increase from preoperative) at 3 years. Flexion/extension range of motion averaged 5.9° (SD 4.8°) at 3 years, and was not statistically different from preoperative (p = 0.471). Heterotopic ossification interfering with segmental motion was noted in 3 patients (10.3 %) at 3 years, none ankylosed (Grade IV). Postoperative improvement in patient-reported outcomes was significant (p < 0.01 for all measures) and maintained through 3-year follow-up. Satisfaction with results was reported by 85 % (51/60) of patients at 2 years and 93 % (28/30) at 3 years. There were no revisions through 3 years postoperative. CONCLUSIONS: The results following XL TDR show good clinical and radiographic outcomes out to 3 years postoperative, with clinically significant improvements in pain, function, and general health, few complications, and high patient satisfaction.
Authors: P Justin Tortolani; Bryan W Cunningham; Mmech Eng; Paul C McAfee; Gwen A Holsapple; Karen A Adams Journal: J Bone Joint Surg Am Date: 2007-01 Impact factor: 5.284
Authors: Wilco C H Jacobs; Niels A van der Gaag; Moyo C Kruyt; Alexander Tuschel; Marinus de Kleuver; Wilco C Peul; Abraham J Verbout; F Cumhur Oner Journal: Spine (Phila Pa 1976) Date: 2013-01-01 Impact factor: 3.468
Authors: Toon F M Boselie; Paul C Willems; Henk van Mameren; Rob A de Bie; Edward C Benzel; Henk van Santbrink Journal: Spine (Phila Pa 1976) Date: 2013-08-01 Impact factor: 3.468
Authors: Scott Blumenthal; Paul C McAfee; Richard D Guyer; Stephen H Hochschuler; Fred H Geisler; Richard T Holt; Rolando Garcia; John J Regan; Donna D Ohnmeiss Journal: Spine (Phila Pa 1976) Date: 2005-07-15 Impact factor: 3.468
Authors: Fred H Geisler; Scott L Blumenthal; Richard D Guyer; Paul C McAfee; John J Regan; J Patrick Johnson; Bradford Mullin Journal: J Neurosurg Spine Date: 2004-09
Authors: Austen David Katz; Dean Cosmo Perfetti; Alan Job; Max Willinger; Jeffrey Goldstein; Daniel Kiridly; Peter Olivares; Alexander Satin; David Essig Journal: Global Spine J Date: 2020-07-31